Ask AI
ProCE Banner Activity

HARMONi-6: Ivonescimab + CT vs Tislelizumab + CT as 1L Therapy for Stage IIIB-IV Squamous NSCLC

Conference Coverage
Slideset

In the HARMONi-6 phase III trial conducted in patients with advanced squamous NSCLC, first-line treatment with ivonescimab plus chemotherapy significantly improved PFS vs tislelizumab plus chemotherapy.

Released: October 27, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc., Gilead Sciences, Inc., Incyte, and Lilly.

AstraZeneca

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

Incyte

Lilly